期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

磁共振特异性对比剂在原发性肝癌诊断中的应用 被引量：8

下载PDF
导出
摘要 原发性肝癌(HCC)的发病率居于全球恶性肿瘤第5位,随着我国乙型肝炎和肝硬化发生率的增加,原发性肝癌的发生率亦随之不断地增加。如果能早期发现小肝癌,将大大提高原发性肝癌患者的5年生存率。虽然Gd-DTPA增强磁共振(MRI)检查技术在肝癌诊断上有较高的敏感性和特异性,但在小肝癌诊断上仍存在一些不足。近几年,随着越来越多的新型对比剂(如细胞特异性对比剂)应用于肝癌的磁共振检查,为早期发现肝癌(尤其是小肝癌),进行及时治疗及提高生存率发挥了重要的作用。本文拟对近几年来肝癌磁共振检查的细胞特异性对比剂应用及其进展做一简单综述。
作者 钟玉凤 唐作华
机构地区 复旦大学附属金山医院放射科 复旦大学附属眼耳鼻喉科医院
出处 《放射学实践》 北大核心 2015年第10期1056-1058,共3页 Radiologic Practice
关键词 肝肿瘤 磁共振成像 诊断
分类号 R735.7 [医药卫生—肿瘤] R445.2 [医药卫生—影像医学与核医学]
  • 相关文献

参考文献21

  • 1Venook AP, Papandreou C, Furuse J, et al. The incidence and epi- demiology of hepatocellular carcinoma: a global and regional per spective[J]. Oncologist, 2010,15 ( suppl 4) : 5-13.
  • 2Ferenci P, Fried M, Labrecque D, et al. Hepatocellular carcinoma (HCC) : a global perspective[J]. J Clinical Gastroenterology, 2010, 44(4):239- 245.
  • 3Ronot M,Vilgrain V. Hepatoeellular carcinoma: diagnostic criteria by imaging techniques[J]. Best Practice g>- Research Clinical Gas- troenterology, 2014,28(5) : 795-812.
  • 4Oprita R, Diaconescu I, Lupu G, et al. Hepatocellular carcinoma a- mong cirrhoties Utility of screening and surveillance programs-re- view article[J]. J Med Life,2014,7(4):477 -480.
  • 5You MW,Kim SY,Kim KW,et al. Recent advances in the imaging of hepatocellular carcinoma[J]. Clin Mol Hepatol, 2015,21 (1) : 95- 103.
  • 6Forner A,Vilana R, Bianchi L, et al. Lack of arterial hypervascw larity at contrast-enhanced ultrasound should not define the priori- ty for diagnostic work up of nodules <22cm[J]. J Hepatol,2015,62 (1),150 -155.
  • 7Bolog N. CT and MR imaging of hepatocellular carcinoma[J]. J Gastrointestinal and Liver Diseases, 2011,20(2) : 181 -189.
  • 8Teerasamit W, Saiviroonporn P, Pongpaibul A, et al. Benefit of double contrast MRI in diagnosis of bepatocellular carcinoma in patients with chronic liver diseases[J]. J Med Assoc Thai,2014,97 (5):540 -547.
  • 9Yu MH,Kim JH,Yoon JH,et al. Small (lcm) hepatocellular carcinomadiagnostic performance and imaging features at gadox eric acid enhanced MR imaging[J]. Radiology, 2014,271 (3) : 748 -760.
  • 10Wang YX. Superparamagnetic iron oxide based MRI contrast a gents:current status of clinical application[J]. Quant Imaging Med Surg,2011,1(1) :35- 40.

二级参考文献19

  • 1程伟中,曾蒙苏.新型多功能磁共振对比剂Gd-EOB-DTPA在肝胆系统病变中的应用[J].临床放射学杂志,2005,24(12):1107-1110. 被引量：15
  • 2Vasanawala SS. MRI of the liver how to do it[J]. Pecliatr Ra- diol,2010,40(4) ;431-437.
  • 3Kanematsu M, Kondo H, Goshima S, et al. Magnetic resonance imaging of hepatocellular carcinoma[J]. Oncology, 2008,75 ( suppl 1) :65-71.
  • 4Balci NC, Semelka RC. Contrast agents for MR imaging of the liver[J].Radiol Clin North Am,2005,43(5) :887-898.
  • 5Reimer P, Schneider G, Schima W. Hepatobiliary contrast agentsfor contrast-enhanced MRI of the liver: properties, clinical deve- lopment and applications[J]. Eur Radiol, 2004,14(4) : 559-578.
  • 6Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, et al. Pre- clinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system[J]. Radiology: 1992,183 (l):59 -64.
  • 7Reimer P,Rummeny EJ,Shamsi K, et al. Phase clinical evalua tion of Gd-EOB-DTPA: dose, safety aspects and pulse sequence[J].Radiology, 1996,199 (1): 177-183.
  • 8Hamm B,Staks T,Mtihler A,et al. Phase I chinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: Safety, pharmacokinetics and MR imaging[J]. Radiology, 1995,195 (3): 785-792.
  • 9Schuhmann-Giampieri G, Mahler M,Roll G, et al. Pharmacokine- tics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast enhanced liver imaging in humans[J]. J Clin Pharma- col, 1997,37(7) : 587-596.
  • 10Clement O, Miler A, Vexler V,et al. Gadolinium-ethoxybenzyl- DTPA,a new liver-specific magnetic resonance contrast agent [J]. Invest Radiol,1992,27(8) :612-619.

共引文献32

同被引文献77

  • 1Masahiro Okada,Kazunari Ishii,Kazushi Numata,Tomoko Hyodo,Seishi Kumano,Masayuki Kitano,Masatoshi Kudo,Takamichi Murakami.Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function?[J].Hepatobiliary & Pancreatic Diseases International,2012,11(3):307-313. 被引量：13
  • 2Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005,55(2) :74-108.
  • 3Bruix J,Sherman M. Management of hepatocellular carcinoma[J]. Hepatology, 2005,42(5) 1208-1036.
  • 4Yamashita Y, Mitsuzaki K, Yi T, et al. Small hepatocellular carci noma in patients with chronic liver damage: prospective compari- son of detection with dynamic MR imaging and helical CT of the whole liver[J]. Radiology, 1996,200(1) : 79-84.
  • 5Scale MK,Catalano OA,Saini S, et al. Hepatobiliary-specific MR contrast agents., role in imaging the liver and biliary tree[J]. Radi- ographics,2009,29(6) :1725-1748.
  • 6Park M J, Kim YK, Lee MW, et al. Small hepatoeellular carcino mas:improved sensitivity by combining gadoxetie acid-enhanced and diffusion-weighted MR imaging patterns[J]. Radiology, 2012, 264(3) : 761-770.
  • 7Krinsky G. Terminology of hepatoeellular nodules in cirrhosis: plea for consistency[J]. Radiology,2002,224(3) :638.
  • 8Bruix J,Sherman M. Management of hepatoeellular carcinoma:an update[J]. Hepatology, 2011,53(3) : 1020-1022.
  • 9Liu X, Zou L, Liu F, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma a metwanalysis[J]. PLoS One, 2013,8(8) : e70896.
  • 10Wu LM,Xu JR,Gu HY,et al. Is liver-specific gadoxetic acid-en- hanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver dis- ease? [J]. Dig Dis Sci,2013,58(11) :3313-3325.

引证文献8

二级引证文献73

放射学实践
2015年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部